Gastric Inhibitory Polypeptide （GIP） which is a significant insulin-releasing hormone of the enteroinsular axis has a functional profile of possible therapeutic value for type 2 diabetes. GIP is an important incretin hormone released into the circulation from endocrine K-cells of the duodenum and jejunum after ingestion of food1. GIP was evaluated for their ability to elevate cellular cAMP production and stimulate insulin secretion. GIP promotes plasma triglyceride clearance in response to oral fat loading and also enhances insulin-dependent inhibition of glycogenolysis in liver.
